Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial

BACKGROUND: The safety and immunogenicity of the coadministration of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV), quadrivalent split-virion inactivated influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults in China is unknown. METHODS: In this ope...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Haiping, Huang, Zhuoying, Chang, Shaoying, Hu, Mei, Lu, Qingbin, Zhang, Yuntao, Wang, Hui, Xiao, Yanhui, Ge, Yonghong, Zou, Yong, Cui, Fuqiang, Han, Shasha, Zhang, Min, Wang, Shengyi, Zhu, Xiaoping, Zhang, Biao, Li, Zhi, Ren, Jia, Chen, Xiao, Ma, Rui, Zhang, Lei, Guo, Xue, Luo, Linyun, Sun, Xiaodong, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334936/
https://www.ncbi.nlm.nih.gov/pubmed/35931636
http://dx.doi.org/10.1016/j.vaccine.2022.07.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334936/
https://www.ncbi.nlm.nih.gov/pubmed/35931636
http://dx.doi.org/10.1016/j.vaccine.2022.07.033

Ejemplares similares